Your Health, We Care

Home > Photo Wall > Honor and qualification

Rozlytrek Approval

Release date: 2024-07-09 16:19:50     Recommended: 82

03L1075_24 恩曲替尼 批文_00.jpg

Rozlytrek is suitable for the treatment of specific lung diseases and other conditions. Entratinib only took less than seven years from entering clinical trials to being approved for market by the FDA, which is enough to prove the therapeutic effect of Rozlytrek.

Company News

Research News

Drug news